Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

Granholm, A, Kjær, M-BN, Munch, MW, Myatra, SN, Vijayaraghavan, BKT, Cronhjort, M, Wahlin, RR, Jakob, SM, Cioccari, L, Vesterlund, GK, Meyhoff, TS, Helleberg, M, Møller, MH, Benfield, T, Venkatesh, B, Hammond, NE, Micallef, S, Bassi, A, John, O, Jha, V, Kristiansen, KT, Ulrik, CS, Jørgensen, VL, Smitt, M, Bestle, MH, Andreasen, AS, Poulsen, LM, Rasmussen, BS, Brøchner, AC, Strøm, T, Møller, A, Khan, MS, Padmanaban, A, Divatia, JV, Saseedharan, S, Borawake, K, Kapadia, F, Dixit, S, Chawla, R, Shukla, U, Amin, P, Chew, MS, Wamberg, CA, Bose, N, Shah, MS, Darfelt, IS, Gluud, C, Lange, T & Perner, A 2022, 'Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia', Intensive Care Medicine, bind 48, nr. 5, s. 580-589. https://doi.org/10.1007/s00134-022-06677-2

APA

CBE

Granholm A, Kjær M-BN, Munch MW, Myatra SN, Vijayaraghavan BKT, Cronhjort M, Wahlin RR, Jakob SM, Cioccari L, Vesterlund GK, Meyhoff TS, Helleberg M, Møller MH, Benfield T, Venkatesh B, Hammond NE, Micallef S, Bassi A, John O, Jha V, Kristiansen KT, Ulrik CS, Jørgensen VL, Smitt M, Bestle MH, Andreasen AS, Poulsen LM, Rasmussen BS, Brøchner AC, Strøm T, Møller A, Khan MS, Padmanaban A, Divatia JV, Saseedharan S, Borawake K, Kapadia F, Dixit S, Chawla R, Shukla U, Amin P, Chew MS, Wamberg CA, Bose N, Shah MS, Darfelt IS, Gluud C, Lange T, Perner A. 2022. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Medicine. 48(5):580-589. https://doi.org/10.1007/s00134-022-06677-2

MLA

Vancouver

Author

Granholm, Anders ; Kjær, Maj-Brit Nørregaard ; Munch, Marie Warrer ; Myatra, Sheila Nainan ; Vijayaraghavan, Bharath Kumar Tirupakuzhi ; Cronhjort, Maria ; Wahlin, Rebecka Rubenson ; Jakob, Stephan M ; Cioccari, Luca ; Vesterlund, Gitte Kingo ; Meyhoff, Tine Sylvest ; Helleberg, Marie ; Møller, Morten Hylander ; Benfield, Thomas ; Venkatesh, Balasubramanian ; Hammond, Naomi E ; Micallef, Sharon ; Bassi, Abhinav ; John, Oommen ; Jha, Vivekanand ; Kristiansen, Klaus Tjelle ; Ulrik, Charlotte Suppli ; Jørgensen, Vibeke Lind ; Smitt, Margit ; Bestle, Morten H ; Andreasen, Anne Sofie ; Poulsen, Lone Musaeus ; Rasmussen, Bodil Steen ; Brøchner, Anne Craveiro ; Strøm, Thomas ; Møller, Anders ; Khan, Mohd Saif ; Padmanaban, Ajay ; Divatia, Jigeeshu Vasishtha ; Saseedharan, Sanjith ; Borawake, Kapil ; Kapadia, Farhad ; Dixit, Subhal ; Chawla, Rajesh ; Shukla, Urvi ; Amin, Pravin ; Chew, Michelle S ; Wamberg, Christian Aage ; Bose, Neeta ; Shah, Mehul S ; Darfelt, Iben S ; Gluud, Christian ; Lange, Theis ; Perner, Anders. / Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. I: Intensive Care Medicine. 2022 ; Bind 48, Nr. 5. s. 580-589.

Bibtex

@article{15b7bce80ff14bc78d630d126e6fc49f,
title = "Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia",
abstract = "PURPOSE: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.METHODS: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero.RESULTS: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22).CONCLUSION: Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.",
keywords = "Corticosteroids, COVID-19, Critical illness, Hypoxaemia, Mortality, Quality of life",
author = "Anders Granholm and Kj{\ae}r, {Maj-Brit N{\o}rregaard} and Munch, {Marie Warrer} and Myatra, {Sheila Nainan} and Vijayaraghavan, {Bharath Kumar Tirupakuzhi} and Maria Cronhjort and Wahlin, {Rebecka Rubenson} and Jakob, {Stephan M} and Luca Cioccari and Vesterlund, {Gitte Kingo} and Meyhoff, {Tine Sylvest} and Marie Helleberg and M{\o}ller, {Morten Hylander} and Thomas Benfield and Balasubramanian Venkatesh and Hammond, {Naomi E} and Sharon Micallef and Abhinav Bassi and Oommen John and Vivekanand Jha and Kristiansen, {Klaus Tjelle} and Ulrik, {Charlotte Suppli} and J{\o}rgensen, {Vibeke Lind} and Margit Smitt and Bestle, {Morten H} and Andreasen, {Anne Sofie} and Poulsen, {Lone Musaeus} and Rasmussen, {Bodil Steen} and Br{\o}chner, {Anne Craveiro} and Thomas Str{\o}m and Anders M{\o}ller and Khan, {Mohd Saif} and Ajay Padmanaban and Divatia, {Jigeeshu Vasishtha} and Sanjith Saseedharan and Kapil Borawake and Farhad Kapadia and Subhal Dixit and Rajesh Chawla and Urvi Shukla and Pravin Amin and Chew, {Michelle S} and Wamberg, {Christian Aage} and Neeta Bose and Shah, {Mehul S} and Darfelt, {Iben S} and Christian Gluud and Theis Lange and Anders Perner",
note = "{\textcopyright} 2022. Springer-Verlag GmbH Germany, part of Springer Nature.",
year = "2022",
month = may,
doi = "10.1007/s00134-022-06677-2",
language = "English",
volume = "48",
pages = "580--589",
journal = "Intensive Care Medicine Experimental",
issn = "0342-4642",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

AU - Granholm, Anders

AU - Kjær, Maj-Brit Nørregaard

AU - Munch, Marie Warrer

AU - Myatra, Sheila Nainan

AU - Vijayaraghavan, Bharath Kumar Tirupakuzhi

AU - Cronhjort, Maria

AU - Wahlin, Rebecka Rubenson

AU - Jakob, Stephan M

AU - Cioccari, Luca

AU - Vesterlund, Gitte Kingo

AU - Meyhoff, Tine Sylvest

AU - Helleberg, Marie

AU - Møller, Morten Hylander

AU - Benfield, Thomas

AU - Venkatesh, Balasubramanian

AU - Hammond, Naomi E

AU - Micallef, Sharon

AU - Bassi, Abhinav

AU - John, Oommen

AU - Jha, Vivekanand

AU - Kristiansen, Klaus Tjelle

AU - Ulrik, Charlotte Suppli

AU - Jørgensen, Vibeke Lind

AU - Smitt, Margit

AU - Bestle, Morten H

AU - Andreasen, Anne Sofie

AU - Poulsen, Lone Musaeus

AU - Rasmussen, Bodil Steen

AU - Brøchner, Anne Craveiro

AU - Strøm, Thomas

AU - Møller, Anders

AU - Khan, Mohd Saif

AU - Padmanaban, Ajay

AU - Divatia, Jigeeshu Vasishtha

AU - Saseedharan, Sanjith

AU - Borawake, Kapil

AU - Kapadia, Farhad

AU - Dixit, Subhal

AU - Chawla, Rajesh

AU - Shukla, Urvi

AU - Amin, Pravin

AU - Chew, Michelle S

AU - Wamberg, Christian Aage

AU - Bose, Neeta

AU - Shah, Mehul S

AU - Darfelt, Iben S

AU - Gluud, Christian

AU - Lange, Theis

AU - Perner, Anders

N1 - © 2022. Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2022/5

Y1 - 2022/5

N2 - PURPOSE: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.METHODS: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero.RESULTS: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22).CONCLUSION: Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.

AB - PURPOSE: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.METHODS: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero.RESULTS: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22).CONCLUSION: Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.

KW - Corticosteroids

KW - COVID-19

KW - Critical illness

KW - Hypoxaemia

KW - Mortality

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85127422999&partnerID=8YFLogxK

U2 - 10.1007/s00134-022-06677-2

DO - 10.1007/s00134-022-06677-2

M3 - Journal article

C2 - 35359168

VL - 48

SP - 580

EP - 589

JO - Intensive Care Medicine Experimental

JF - Intensive Care Medicine Experimental

SN - 0342-4642

IS - 5

ER -

ID: 76290816